Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | £1 | £3 | £5 | £3 |
| % Growth | -73.7% | -28.4% | 59.7% | – |
| Cost of Goods Sold | £1 | £2 | £3 | £2 |
| Gross Profit | £0 | £1 | £2 | £1 |
| % Margin | 22.9% | 42.8% | 38.3% | 44.2% |
| R&D Expenses | £2 | £2 | £4 | £6 |
| G&A Expenses | £9 | £12 | £9 | £6 |
| SG&A Expenses | £11 | £13 | £10 | £6 |
| Sales & Mktg Exp. | £2 | £1 | £1 | £1 |
| Other Operating Expenses | -£13 | -£14 | -£9 | -£5 |
| Operating Expenses | £0 | £1 | £2 | £1 |
| Operating Income | -£17 | -£16 | -£14 | -£12 |
| % Margin | -1,874.1% | -460.4% | -301.4% | -407.4% |
| Other Income/Exp. Net | £1 | -£6 | -£7 | -£0 |
| Pre-Tax Income | -£18 | -£21 | -£21 | -£15 |
| Tax Expense | £0 | £0 | £0 | -£0 |
| Net Income | -£18 | -£21 | -£20 | -£16 |
| % Margin | -1,967.4% | -614.6% | -430% | -535.6% |
| EPS | -0.47 | -7.11 | -7.63 | -7.01 |
| % Growth | 93.4% | 6.8% | -8.8% | – |
| EPS Diluted | -0.47 | -7.07 | -7.63 | -6.95 |
| Weighted Avg Shares Out | 37 | 3 | 3 | 2 |
| Weighted Avg Shares Out Dil | 37 | 3 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £1 | £1 | £0 | £0 |
| EBITDA | -£16 | -£20 | -£20 | -£15 |
| % Margin | -1,770% | -593.9% | -429.2% | -491.9% |